HRP20130167T1 - Spojevi korisni za inhibiranje chk1 - Google Patents
Spojevi korisni za inhibiranje chk1 Download PDFInfo
- Publication number
- HRP20130167T1 HRP20130167T1 HRP20130167AT HRP20130167T HRP20130167T1 HR P20130167 T1 HRP20130167 T1 HR P20130167T1 HR P20130167A T HRP20130167A T HR P20130167AT HR P20130167 T HRP20130167 T HR P20130167T HR P20130167 T1 HRP20130167 T1 HR P20130167T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- salt
- compound
- aminopropoxy
- pyrazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13817608P | 2008-12-17 | 2008-12-17 | |
| PCT/US2009/067437 WO2010077758A1 (en) | 2008-12-17 | 2009-12-10 | Compounds useful for inhibiting chk1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130167T1 true HRP20130167T1 (hr) | 2013-03-31 |
Family
ID=42079067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130167AT HRP20130167T1 (hr) | 2008-12-17 | 2009-12-10 | Spojevi korisni za inhibiranje chk1 |
Country Status (37)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314108B2 (en) * | 2008-12-17 | 2012-11-20 | Eli Lilly And Company | 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts |
| AR083575A1 (es) * | 2010-11-08 | 2013-03-06 | Lilly Co Eli | Aminopirazoles para inhibir la proteinquinasa chk1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| TWI725041B (zh) * | 2015-07-23 | 2021-04-21 | 美商美國禮來大藥廠 | 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑 |
| AR106772A1 (es) * | 2015-12-07 | 2018-02-14 | Lilly Co Eli | Sales de (s)-lactato |
| US20180228795A1 (en) * | 2015-12-15 | 2018-08-16 | Eli Lilly And Company | Combination therapy for cancer |
| HRP20220351T1 (hr) | 2016-02-04 | 2022-05-13 | Pharmaengine, Inc. | 3,5-disupstituirani pirazoli korisni kao inhibitori kinaze 1 kontrolne točke (chk1), i njihove pripreme i primjene |
| MX2019011506A (es) | 2017-03-31 | 2019-11-01 | Seattle Genetics Inc | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| CN112457306A (zh) | 2019-09-06 | 2021-03-09 | 上海瑛派药业有限公司 | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 |
| US11634424B2 (en) | 2019-11-29 | 2023-04-25 | Medshine Discovery Inc. | Diazaindole derivative and use thereof as CHK1 inhibitor |
| WO2021119236A1 (en) | 2019-12-10 | 2021-06-17 | Seagen Inc. | Preparation of a chk1 inhibitor compound |
| KR20230115988A (ko) | 2020-11-30 | 2023-08-03 | 스미토모 파마 가부시키가이샤 | 5-헤테로아릴-1h-피라졸-3-아민 유도체 |
| US11564920B2 (en) | 2020-11-30 | 2023-01-31 | Sumitomo Pharma Co., Ltd. | 5-heteroaryl-1H-pyrazol-3-amine derivative |
| BR112023024571A2 (pt) | 2021-05-27 | 2024-02-06 | Boundless Bio Inc | Inibidores de quinase do ponto de verificação 1 (chk1) e usos dos mesmos |
| GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| GB202107932D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | Preparation of a CHK1 Inhibitor Compound |
| JPWO2023120696A1 (enExample) | 2021-12-24 | 2023-06-29 | ||
| JPWO2023229032A1 (enExample) * | 2022-05-27 | 2023-11-30 | ||
| JP7546104B2 (ja) * | 2022-05-27 | 2024-09-05 | 住友ファーマ株式会社 | ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体からなる医薬 |
| GB202213792D0 (en) | 2022-09-21 | 2022-11-02 | Benevolentai Bio Ltd | New compounds and method |
| GB202403910D0 (en) | 2024-03-19 | 2024-05-01 | Benovental Cambridge Ltd | New processes and intermediates for pharmaceutical products |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040034038A1 (en) * | 2002-08-13 | 2004-02-19 | Goaquan Li | Urea kinase inhibitors |
| MXPA06000933A (es) * | 2003-07-25 | 2006-03-30 | Pfizer | Compuestos de aminopirazol y uso como inhibidores de chk1. |
| WO2008117050A1 (en) * | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| US20090270418A1 (en) * | 2008-01-09 | 2009-10-29 | Marianne Sloss | Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith |
-
2009
- 2009-11-26 PA PA20098850801A patent/PA8850801A1/es unknown
- 2009-12-01 JO JO2009456A patent/JO2886B1/en active
- 2009-12-03 TW TW098141394A patent/TWI436996B/zh active
- 2009-12-03 AR ARP090104673A patent/AR074471A1/es not_active Application Discontinuation
- 2009-12-10 PL PL09768586T patent/PL2379532T3/pl unknown
- 2009-12-10 AU AU2009333433A patent/AU2009333433B2/en not_active Ceased
- 2009-12-10 EP EP09768586A patent/EP2379532B1/en active Active
- 2009-12-10 PT PT97685861T patent/PT2379532E/pt unknown
- 2009-12-10 SI SI200930559T patent/SI2379532T1/sl unknown
- 2009-12-10 HR HRP20130167AT patent/HRP20130167T1/hr unknown
- 2009-12-10 EA EA201170834A patent/EA018118B1/ru not_active IP Right Cessation
- 2009-12-10 CA CA2746423A patent/CA2746423C/en not_active Expired - Fee Related
- 2009-12-10 WO PCT/US2009/067437 patent/WO2010077758A1/en not_active Ceased
- 2009-12-10 MX MX2011006603A patent/MX2011006603A/es active IP Right Grant
- 2009-12-10 KR KR1020117013801A patent/KR101301777B1/ko not_active Expired - Fee Related
- 2009-12-10 JP JP2011542264A patent/JP5705743B2/ja active Active
- 2009-12-10 DK DK09768586.1T patent/DK2379532T3/da active
- 2009-12-10 BR BRPI0922468-8A patent/BRPI0922468A2/pt active Search and Examination
- 2009-12-10 MY MYPI2011002767A patent/MY156998A/en unknown
- 2009-12-10 SG SG2011044401A patent/SG172222A1/en unknown
- 2009-12-10 CN CN200980150018.7A patent/CN102245597B/zh active Active
- 2009-12-10 ES ES09768586T patent/ES2401558T3/es active Active
- 2009-12-10 PE PE2011001140A patent/PE20120077A1/es active IP Right Grant
- 2009-12-10 UA UAA201107564A patent/UA101998C2/ru unknown
- 2009-12-10 RS RS20130153A patent/RS52739B/sr unknown
- 2009-12-10 NZ NZ593440A patent/NZ593440A/xx not_active IP Right Cessation
-
2011
- 2011-05-26 IL IL213160A patent/IL213160A/en not_active IP Right Cessation
- 2011-05-27 ZA ZA2011/03946A patent/ZA201103946B/en unknown
- 2011-06-01 HN HN2011001446A patent/HN2011001446A/es unknown
- 2011-06-10 TN TN2011000298A patent/TN2011000298A1/fr unknown
- 2011-06-13 DO DO2011000185A patent/DOP2011000185A/es unknown
- 2011-06-14 MA MA33944A patent/MA32901B1/fr unknown
- 2011-06-15 CO CO11074829A patent/CO6382122A2/es active IP Right Grant
- 2011-06-16 CL CL2011001463A patent/CL2011001463A1/es unknown
- 2011-06-16 EC EC2011011136A patent/ECSP11011136A/es unknown
- 2011-06-17 CR CR20110339A patent/CR20110339A/es unknown
-
2013
- 2013-04-11 CY CY20131100305T patent/CY1113930T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130167T1 (hr) | Spojevi korisni za inhibiranje chk1 | |
| ME02119B (me) | Spojevi korisni za inhibiranje chk1 | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| JP2013541586A5 (enExample) | ||
| HRP20170634T4 (hr) | Kristalni oblik od 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida | |
| ES2579235T3 (es) | Profármacos Alquilantes de Fosforamidato | |
| JP2011126896A5 (enExample) | ||
| ME02663B (me) | Derivati benzimidazola kao inhibitori pi3 kinaze | |
| HRP20170736T1 (hr) | Indoli | |
| AR117804A2 (es) | Composiciones farmacéuticas que comprenden una cantidad efectiva de dioxicarbonato de lantano y compuestos de dioxicarbonato de lantano | |
| JP2010518110A5 (enExample) | ||
| JP2017532360A5 (enExample) | ||
| ES2703592T3 (es) | Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno | |
| HRP20150531T1 (hr) | Pirazolilaminopiridini kao inhibitori fak | |
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| JP2015505542A5 (enExample) | ||
| HRP20191860T1 (hr) | Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka | |
| HRP20191979T1 (hr) | Heteoarilni spojevi koji su korisni kao inhibitori sumo-aktivirajućeg enzima | |
| HRP20131051T1 (hr) | Inhibitori proteinskih kinaza | |
| SI2970216T1 (en) | Biaryl-amide compounds as kinase inhibitors | |
| ME02805B (me) | Inhibitori cdc7 | |
| CN105906631A (zh) | 用于激酶调节的化合物和方法及其适应症 | |
| JP2012526808A5 (enExample) | ||
| HRP20210144T1 (hr) | Kompozicije koje sadrže inhibitor lizin specifične demetilaze-1 koje imaju pirimidinski prsten i njihova primjena u liječenju raka | |
| HRP20131052T1 (hr) | Agonisti mglu2 |